ArticleAgriculture and human values2026
Friends with benefits: What constitutes a 'benefit' in Access and Benefit Sharing (ABS) for plant genetic resources?
Article in Agriculture and human values, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
International conventions play an important role in regulating access to plant genetic resources. These regulations must balance the goal of ensuring wide access to plant genetic resources with doing this in a fair way. This is a central dilemma in achieving just transitions: how to move towards more sustainable societies in ways that are equitable and fair way. In regulations for plant genetic resources, this balance is struck with the concept of Access and Benefit Sharing (ABS). Under the bilateral system of the Nagoya Protocol, ABS requires anyone seeking access to a genetic resource to agree with the provider of that resource on what benefits will be shared. However, the lack of clarity as to what constitutes a 'benefit' has been a major stumbling block in the establishment of ABS agreements and therefore the exchange of genetic material. This article fills this gap by identifying and characterizing what types of benefits have been included in the ABS agreements established successfully under the Nagoya Protocol. We found that ABS agreements can include an incredible variety of types of monetary and non-monetary benefits, that can contribute to a wide range of different objectives, and which are not necessarily related to the benefits obtained from using the genetic resource. By providing more clarity over what benefits can be shared, this overview and characterization of benefits shared in successful ABS agreements supports the development of successful future ABS agreements. We argue that the experiences of developing Access and Benefit Sharing into a workable concept may offer valuable insights for how regulations can play a role in just transitions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.